• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model

tetano

Editor, Senior Moderator
Nat Commun


. 2024 Aug 10;15(1):6867.
doi: 10.1038/s41467-024-50903-y. De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model

Haohuai He[SUP] #[/SUP][SUP] 1 2 [/SUP], Bing He[SUP] #[/SUP][SUP] 3 [/SUP], Lei Guan[SUP] #[/SUP][SUP] 4 [/SUP], Yu Zhao[SUP] 1 [/SUP], Feng Jiang[SUP] 1 [/SUP], Guanxing Chen[SUP] 2 [/SUP], Qingge Zhu[SUP] 4 [/SUP], Calvin Yu-Chian Chen[SUP] 5 6 7 8 9 [/SUP], Ting Li[SUP] 10 [/SUP], Jianhua Yao[SUP] 11 [/SUP]



Affiliations
Abstract

Artificial Intelligence (AI) techniques have made great advances in assisting antibody design. However, antibody design still heavily relies on isolating antigen-specific antibodies from serum, which is a resource-intensive and time-consuming process. To address this issue, we propose a Pre-trained Antibody generative large Language Model (PALM-H3) for the de novo generation of artificial antibodies heavy chain complementarity-determining region 3 (CDRH3) with desired antigen-binding specificity, reducing the reliance on natural antibodies. We also build a high-precision model antigen-antibody binder (A2binder) that pairs antigen epitope sequences with antibody sequences to predict binding specificity and affinity. PALM-H3-generated antibodies exhibit binding ability to SARS-CoV-2 antigens, including the emerging XBB variant, as confirmed through in-silico analysis and in-vitro assays. The in-vitro assays validate that PALM-H3-generated antibodies achieve high binding affinity and potent neutralization capability against spike proteins of SARS-CoV-2 wild-type, Alpha, Delta, and the emerging XBB variant. Meanwhile, A2binder demonstrates exceptional predictive performance on binding specificity for various epitopes and variants. Furthermore, by incorporating the attention mechanism inherent in the Roformer architecture into the PALM-H3 model, we improve its interpretability, providing crucial insights into the fundamental principles of antibody design.


 
Back
Top Bottom